Sleutelpositie breidt de wereldwijde aanwezigheid van Amylyx uit

CAMBRIDGE, Massachusetts–(BUSINESS WIRE)– Amylyx Pharmaceuticals, Inc. heeft vandaag de benoeming aangekondigd van Stéphanie Hoffmann-Gendebien, MBA, als hoofd, algemeen directeur in Europa, het Midden-Oosten en Afrika (EMEA). Mevrouw Hoffmann-Gendebien heeft meer dan 20 jaar leidinggevende ervaring in de farmaceutische en biotechnologische sector met diepgaande expertise in de ontwikkeling en commercialisering van weesgeneesmiddelen. De eerste Europese entiteit van Amylyx, Amylyx Pharmaceuticals EMEA BV, is opgericht in Nederland en vestigt een aanwezigheid en team in Europa om dichter bij de patiëntengemeenschap, kenniscentra in de geneeskunde en regelgevende instanties te staan in regio’s waarvoor mevr. Hoffmann-Gendebien zal leidinggeven aan en toezicht houden op Amylyx. Amylyx zal haar EMEA-hoofdkantoor vestigen in het Zuidas-district, Amsterdam, en plant een toekomstige uitbreiding naar het Midden-Oosten en Afrika.

Amylyx Pharmaceuticals Hires Stéphanie Hoffmann-Gendebien, MBA, as Head, General Manager EMEA

Key hire expands Amylyx’ global presence

CAMBRIDGE, Mass.–(BUSINESS WIRE)– Amylyx Pharmaceuticals, Inc. today announced the appointment of Stéphanie Hoffmann-Gendebien, MBA, as Head, General Manager in Europe, the Middle East and Africa (EMEA). Ms. Hoffmann-Gendebien brings more than 20 years of leadership experience in the pharmaceutical and biotechnology industries with deep expertise in orphan drug development and commercialization. The first European entity of Amylyx, Amylyx Pharmaceuticals EMEA B.V., is incorporated in the Netherlands and is establishing a presence and team in Europe in order to be closer to the patient community, centers of excellence in medicine and regulatory authorities in regions for which Ms. Hoffmann-Gendebien will manage and oversee at Amylyx. Amylyx will establish its EMEA headquarters in the Zuidas district, Amsterdam, and plans a future expansion into the Middle East and Africa markets.

“At Amylyx, we are determined to help people living with ALS around the world. By expanding our organization in Europe, we can build deeper relationships with local ALS communities and understand their unique needs. With Stéphanie’s extensive global commercial and rare disease experience, and talent for developing long lasting partnerships with advocacy groups, researchers and clinicians, we are confident in her ability to lead Amylyx’ European organization,” said Margaret Olinger, Chief Commercial Officer at Amylyx. “Alongside an already impressive track record, we are certain with Stéphanie’s hands-on leadership style and can-do attitude, she will help us build an incredible team and significant presence across the continent. We’re truly honored to have her join the Amylyx team.”

In her career, Ms. Hoffmann-Gendebien has successfully led the launch of two orphan drugs in Europe and directed global market development, global patient advocacy, European market access and European launch planning for two additional orphan drugs. Most recently, Ms. Hoffmann-Gendebien served as managing director and founding partner of GH PARTNERS, a management consulting company providing consulting services for biotechnology companies involved in rare diseases and orphan drug development. GH PARTNERS provided guidance and consulting to companies related to market development, market access, patient advocacy, general management, orphan drug launch planning and commercialization.

“I was inspired by what I learned about the dedication and urgency with which the entire Amylyx team works to effectively advance AMX0035 through the clinical and commercial development process to help the global ALS community,” said Ms. Hoffmann-Gendebien. “Their willingness to listen and learn from advocacy groups to understand the unique needs of people with ALS is astonishing and makes me proud to join the company. Amylyx is at the forefront of advancing new treatments in neurodegenerative diseases and I am delighted to have the opportunity to develop this organization’s European presence and build out an agile team to serve this market.”

Prior to joining Amylyx, Ms. Hoffmann-Gendebien served as vice president, general manager, Europe, Middle East & Africa (EMEA) at Clementia Pharmaceuticals Inc. Prior to Clementia, she was the European director of strategic market development at Enobia Pharma (Alexion Pharmaceuticals, Inc.) and held roles of increasing responsibility in the therapeutics division Genzyme Europe BV (now Sanofi Genzyme). She serves on the board of directors at Secoya Technologies, a role she has held since April 2020, and volunteers with the European Organisation for Rare Diseases (EURORDIS), a non-governmental patient-driven alliance of rare disease patient organizations. Ms. Hoffmann-Gendebien received a bachelor’s degree in chemistry and an MBA from the Université catholique de Louvain in Louvain-la-Neuve, Belgium.

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc. is a pharmaceutical company working on developing a novel therapeutic for Amyotrophic Lateral Sclerosis (ALS), Alzheimer’s disease and other neurodegenerative diseases. For more information, visit www.amylyx.com and follow us on LinkedIn and Twitter.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211026005775/en/

Contacts

Becky Gohsler

Finn Partners

(646) 307-6307

Becky.Gohsler@finnpartners.com